Clinical Trial Update: Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study- [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial assessing the Salmeterol/Fluticasone Propionate HFA MDI combination in asthma has completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Advair HFA (salmeterol/fluticasone propionate) inhalation aerosol (salmeterol/fluticasone propionate)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Bronchial Asthma | Phase 3 | Status: COMPLETED | Results posted: 2009-08-04